← All trials
NCT05352646
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Apr 29, 2022
- Last posted
- Oct 21, 2022
- Enrollment
- 26
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Newish Technology (Beijing) Co.,Ltd.Lead sponsor
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.